Navigation Links
Human Genome Sciences Announces Fourth-Quarter and Full-Year 2008 Financial Results and Key Developments
Date:2/26/2009

ng cash position, strong partners in GSK and Novartis, and multiple product opportunities to drive future value."

HGS also announced that it has repurchased $106.2 million principal amount of its outstanding convertible debt at a cost of $50.0 million in cash. The repurchase includes $82.9 million principal amount of the Company's 2 1/4% Convertible Subordinated Notes Due October 2011, and $23.3 million principal amount of the Company's 2 1/4% Convertible Subordinated Notes Due August 2012.

"We are pleased that we were able to capitalize on an opportunity to further strengthen our balance sheet by reducing our debt at reasonable prices," said Tim Barabe, Senior Vice President and Chief Financial Officer, HGS. "Our cash position remains strong and is sufficient to take us through the availability of Phase 3 data and the filing of marketing applications for our lead products, while also funding development of our product pipeline."

FINANCIAL RESULTS

HGS reported increased revenues of $48.2 million for the year ended December 31, 2008, compared with revenues of $41.9 million for the same period in 2007. Revenues for 2008 included $35.4 million recognized from the Albuferon agreement with Novartis, and $6.5 million in revenue recognized from the LymphoStat-B agreement with GSK.

The Company reported a net loss for 2008 of $244.9 million ($1.81 per share), compared with a net loss of $262.4 million ($1.95 per share) for 2007. The decreased net loss for 2008 was due primarily to a gain on the sale of CoGenesys stock of $32.5 million ($0.24 per share), partially offset by a decrease in investment income and a charge for impaired investments in debt issued by Lehman Brothers Holdings, Inc., of $6.3 million ($0.04 per share).

Net cash burn for 2008 totaled $244.8 million, compared with $179.9 million in 2007. The increase in net cash burn primarily reflected va
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. IlluminOss Medical Announces First Human Case Utilizing a Unique, New, Minimally Invasive Technology for Fracture Repair is Performed at Medical Hospital del Trabajadar in Santiago, Chile
2. GeoVax Starts Injections for Phase 2a Human HIV/AIDS Vaccine Trial in USA
3. FDA Grants Priority Review of a Supplemental Biologics License Application for Cinryze(TM) C1 Inhibitor (Human) as Treatment for Acute Attacks of Hereditary Angioedema (HAE)
4. Cloned Human Embryos Successfully Reprogrammed Using Human - But Not Animal - Eggs
5. Human Genome Sciences Begins Delivery of First-in-Class Anthrax Treatment to U.S. Strategic National Stockpile
6. Mardil Inc. Advances Its Novel Cardiac Device to First-In-Human Trials for Mitral Valve Regurgitation
7. Modigene Announces Positive Results of Pilot Toxicity Study of Its Long-Acting Human Growth Hormone hGH-CTP
8. Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2009 Goals at JPMorgan Healthcare Conference
9. Cequent to Present First Proof of Activity of an Oral RNAi Drug in Non-Human Primates at February Keystone Conference
10. 2008 Human Research Protection Award Recipients Announced
11. USD 12.5 m Funding for the Development of Intercells Vaccine Patch System for Pandemic Influenza From U.S. Department of Health and Human Services (HHS)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 MultiCell Technologies, Inc. (OTC Bulletin Board: ... application concerning composition of matter, biological targets, mechanism of ... death.  This patent application describes a ... molecules (VSRNAs) which interfere with the basic homeostatic cellular ...
(Date:1/15/2014)... 15, 2014 Reportlinker.com announces that a ... its catalogue: PharmaPoint: ... Market Analysis to 2022 ... - India Drug Forecast and Market Analysis ...
(Date:1/15/2014)... Ohio , Jan. 15, 2014  A novel wearable injector ... easy and painless for patients to self-inject prescription drugs in ... disorders, including cancer, blood diseases, autoimmune deficiencies, and genetic disorders.  ... to grow to $220B by 2018, according to analysts.   Many ...
Breaking Medicine Technology:MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2
... Orthopedics, Inc., the world leader in PyroCarbon orthopedic ... Modular Total Shoulder System. This newly designed system ... shoulder arthroplasty with one implant system. ... in collaboration with Joseph Abboud, M.D, Phillip Duke, ...
... Calif., Sept. 2 NewCardio (OTC Bulletin Board: ... Vincent Renz, Jr., NewCardio,s President and CEO, purchased 128,000 shares ... two weeks following the Company,s filing of its SEC Form ... 30, 2010. "As discussed on our August ...
Cached Medicine Technology:Ascension Orthopedics Receives FDA Approval for TITAN™ Modular Total Shoulder System 2NewCardio CEO Increases Equity Position 2NewCardio CEO Increases Equity Position 3NewCardio CEO Increases Equity Position 4
(Date:7/9/2014)... risen dramatically in Western societies. One frequently cited reason ... have fewer infections than previous generations, thereby delaying maturation ... at Sahlgrenska Academy, University of Gothenburg, monitored children until ... immune system in relation to allergic disease. All of ... Gtaland Region, half of them on farms that produced ...
(Date:7/8/2014)... kidney donors enjoy similar longevity and cardiovascular health as ... published in the American Journal of Transplantation . ... considering donation and the transplant professionals caring for them. ... by individuals aged 55 years and older has become ... disease, and heart disease, the removal of a kidney ...
(Date:7/8/2014)... Defense Advanced Research Projects Agency (DARPA) awarded Lawrence ... to develop an implantable neural device with the ... brain to help restore memory, DARPA officials announced ... understanding that memory is a process in which ... information, store it and retrieve it. Certain types ...
(Date:7/8/2014)... found to be three times higher when auditors were ... auditors present, according to a study in a major ... "Quantification of the Hawthorne effect in hand hygiene compliance ... study," published today on-line in the BMJ Quality ... Srigley, who did the study as part of her ...
(Date:7/8/2014)... discovered a biomarker that could give expecting mothers and ... predict that a pregnant woman may develop preeclampsia, at ... , Preeclampsia is a cardiovascular disorder generally occurring late ... creating immediate and potentially lifelong risks to both mother ... in the urine, and is typically diagnosed in the ...
Breaking Medicine News(10 mins):Health News:Study finds kidney donation safe for healthy older adults 2Health News:DARPA selects Lawrence Livermore to develop world's first neural device to restore memory 2Health News:DARPA selects Lawrence Livermore to develop world's first neural device to restore memory 3Health News:Health-care worker hand hygiene rates increase three-fold when auditors visible 2Health News:Health-care worker hand hygiene rates increase three-fold when auditors visible 3Health News:UI researchers find early predictor for preeclampsia 2Health News:UI researchers find early predictor for preeclampsia 3
... Actor Joe Pantoliano,reveals a personal history of ... untreated bipolar disorder, in a guest blog entry, ... on Mental,Illness (NAMI)., Pantoliano,s entry comes during ... days before the opening of his latest film, ...
... shows , TUESDAY, Oct. 9 (HealthDay News) -- U.S. ... to a treatment for the hereditary, progressive neurological disorder ... molecule called C2-8 appears to reduce HD-related neurological damage ... team from the MassGeneral Institute for Neurological Disorders (MIND), ...
... anxiety, low control doubles recurrent heart attack risk, study finds ... doubles the risk that someone who has had a heart ... finds. , Other studies have shown that workplace stress boosts ... anxieties with recurrent heart attacks and other major events, the ...
... scientists have developed a potentially novel way to fight ... of radiation inside cancer cells, unlike current treatments that ... the outside and cause unwanted side effects. , ... new radiation delivery system proved able to specifically target ...
... 9 The March of,Dimes congratulates Mario R. Capecchi, ... Smithies, D.Phil., FRS, former recipients of the,March of Dimes ... in Physiology or Medicine. The Nobel Committee announced ... of principles for introducing specific gene,modifications in mice by ...
... Oct. 9 Health plans are expecting premium,rate increases ... last,year,s expectation of 8.2%. This is the fourth consecutive ... conducted this survey in September of 2007. The survey,contained ... nationwide. Separately, the survey notes that the East ...
Cached Medicine News:Health News:Actor Joe Pantoliano Discloses Depression; Talks About His Latest Movie and His Sensitive Side 2Health News:Molecule Promising Against Huntington's Disease 2Health News:Stressful Jobs Hard on the Heart 2Health News:Stressful Jobs Hard on the Heart 3Health News:Inside job: new radioactive agents for colon cancer work inside cells 2Health News:Nobel Honors 3 Former March of Dimes Prize Recipients 2
... over 20 years of experience in ... the Life Sciences, the Freedom EVO ... possibilities for expansion according to future ... software, Freedom EVOware, each system is ...
... EVO Clinical is an open platform for clinical ... in deck sizes of 75, 100, 150 ... instrument for your laboratory space and throughput requirements. ... features to allow new applications and to evolve ...
... liquid handling system that ... of up to three ... the same worksurface. Offered ... solutions for targeted applications ...
... The AccelNet Laboratory Automation Network ... clinical chemistry systems, an automated sample ... manager to create a single, powerful ... ideal for laboratories that need a ...
Medicine Products: